DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Hofheinz RD. et al
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO..
ASCO 2020 Abstract 4502
Access:
We do not assume any responsibility for the contents of the web pages of other providers.